A novel small compound TOIDC suppresses lipogenesis via SREBP1-dependent signaling to curb MAFLD.

ABSTRACT:

Background

Inhibition of hepatic lipogenesis is widely regarded as an effective treatment for metabolic-associated fatty liver disease (MAFLD), although numerous related drugs have failed to reach clinical application. The goal of this study is to identify a novel small compound that can effectively treat MAFLD.

Methods

Primary hepatocytes were first exposed to palmitic acid and oleic acid, then treated with compounds prior to high through screening for cellular lipid content. The efficacy of these compounds was measured by Nile Red staining and triglyceride analysis. The potential cellular toxicity caused by these compounds was evaluated by CCK8 assay. qPCR and Western blot were used to determine expression of RNAs and proteins, respectively. The compound was intraperitonea

SUBMITTER: Shao Y 

PROVIDER: S-EPMC9727880 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature